Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Cephalexin
Drug ID BADD_D00412
Description Cephalexin is the first of the first generation cephalosporins.[A179071,A179074] This antibiotic contains a beta lactam and a dihydrothiazide.[A179071] Cephalexin is used to treat a number of susceptible bacterial infections through inhibition of cell wall synthesis.[A179083,Label] Cephalexin was approved by the FDA on 4 January 1971.[L6547]
Indications and Usage Cephalexin is indicated for the treatment of certain infections caused by susceptible bacteria.[Label,L6550,L6553] These infections include respiratory tract infections, otitis media, skin and skin structure infections, bone infections, and genitourinary tract infections.[Label,L6550,L6553]
Marketing Status approved; investigational; vet_approved
ATC Code J01DB01
DrugBank ID DB00567
KEGG ID D00263; D00906
MeSH ID D002506
PubChem ID 27447
TTD Drug ID D0Z5EM
NDC Product Code 80425-0006; 43063-536; 43063-678; 50268-152; 53002-2182; 53002-2260; 55289-057; 62250-801; 63629-9206; 67877-545; 68071-2249; 68071-4429; 70518-3066; 70934-040; 72789-251; 80425-0005; 0093-2238; 0093-3145; 0093-3147; 50090-0219; 53002-2181; 63629-8184; 63629-8858; 63629-9207; 68071-2889; 68071-4434; 68071-4516; 68788-7796; 70518-3362; 70518-3378; 72789-252; 76420-034; 42708-017; 42708-145; 50090-3199; 62135-480; 62250-802; 63187-046; 63629-7742; 63629-8854; 63629-9436; 65862-018; 67877-254; 69043-008; 70518-3059; 63629-4222; 67877-255; 68071-4355; 68788-9713; 70518-3448; 80425-0121; 65862-338; 43063-497; 53002-2540; 62135-481; 63629-8855; 63629-8857; 63629-9198; 63629-9199; 63629-9201; 68180-440; 68180-441; 68788-7761; 68788-9539; 71205-553; 76420-287; 76420-288; 80425-0004; 0093-2240; 0093-4177; 0143-9769; 0143-9770; 50268-151; 60687-152; 63187-205; 63629-8856; 63629-9435; 67877-219; 67877-220; 68071-2246; 68788-7938; 70518-2273; 82982-024; 24979-155; 42291-209; 42582-211; 42582-212; 43063-634; 50090-3427; 62135-711; 63629-7927; 63629-9202; 63629-9205; 67877-544; 68071-4465; 72162-1833; 42708-070; 50090-0220; 53002-2180; 60687-163; 61919-606; 62135-710; 63629-7739; 63629-9203; 65862-019; 68071-4406; 68071-5038; 68071-5241; 68180-121; 68788-7529; 68788-9326; 69043-009; 42708-100; 50090-2749; 55289-058; 63629-7743; 63629-9200; 67296-0246; 68180-122; 70518-3595; 76420-035; 59651-230; 0093-4175; 24979-154; 42291-208; 50090-3202; 50090-3252; 50090-6445; 63629-7740; 63629-9204; 68071-2726; 68071-2940; 68788-9538; 69778-930; 69778-931; 71205-591; 71205-672; 72287-310; 76420-052; 45865-428; 50090-4795
UNII OBN7UDS42Y
Synonyms Cephalexin | Cefalexin | Cephalexin Hydrochloride | Cephalexin Monohydrochloride, Monohydrate | Cephalexin, (6R-(6alpha,7alpha(R*)))-Isomer | Cephalexin, (6R-(6alpha,7beta(S*)))-Isomer | Cephalexin, (6R-(6alpha,7beta))-Isomer | Cephalexin, Monosodium Salt | Cephalexin Monohydrochloride | Ceporexine | Palitrex | Cephalexin Monohydrate | Cephalexin Dihydride | Cephalexin Hemihydrate | 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((aminophenylacetyl)amino)-3-methyl-8-oxo-, (6R-(6alpha,7beta(R*)))- | Cephalexin, Monosodium Salt, (6R-(6alpha,7beta))-Isomer
Chemical Information
Molecular Formula C16H17N3O4S
CAS Registry Number 15686-71-2
SMILES CC1=C(N2C(C(C2=O)NC(=O)C(C3=CC=CC=C3)N)SC1)C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Feeling hot08.01.09.009--Not Available
Flatulence07.01.04.0020.000017%
Flushing24.03.01.002; 23.06.05.003; 08.01.03.0250.000088%
Gastritis07.08.02.001--
Gastrooesophageal reflux disease07.02.02.0030.000017%
Gastrointestinal disorder07.11.01.001--Not Available
Gastrointestinal pain07.01.05.005--
Genital candidiasis21.10.03.001; 11.03.03.002--Not Available
Gout15.01.06.001; 14.09.01.001--Not Available
Haematochezia24.07.02.012; 07.12.02.0030.000017%Not Available
Haemoglobin13.01.05.018--Not Available
Haemolytic anaemia01.06.03.0020.000017%Not Available
Haemorrhage intracranial24.07.04.003; 17.08.01.008--
Hallucination19.10.04.003--
Headache17.14.01.001--
Hemiparesis17.01.04.0010.000017%
Hepatic failure09.01.03.0020.000017%
Hepatic function abnormal09.01.02.001--Not Available
Hepatitis09.01.07.004--Not Available
Hepatomegaly09.01.05.001--Not Available
Hypersensitivity10.01.03.0030.000326%
Hypotension24.06.03.0020.000072%
Immune system disorder10.02.01.001--Not Available
Incoherent19.10.03.006; 17.02.08.002--Not Available
Injection site inflammation08.02.03.008; 12.07.03.009--Not Available
Injection site reaction12.07.03.015; 08.02.03.014--
Jarisch-Herxheimer reaction10.02.01.0020.000034%Not Available
Jaundice23.03.03.030; 09.01.01.004; 01.06.04.0040.000046%Not Available
Jaundice cholestatic09.01.01.005--Not Available
Joint swelling15.01.02.0040.000026%Not Available
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 8 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene